AI-driven healthcare company

Saving Lives by Detecting Cancer Early

Helio Genomics is on a mission to make cancer detection simple, affordable, and early, when it is most treatable. With a single blood draw, we help more people find cancer at the stage they are most likely to beat it.

Explore Our Platform Discover HelioLiver

Validated in the CLiMB trial Published in the Journal of Hepatology

Helio Genomics scientist analyzing a blood-based sample in the lab

90% survival rate when cancer is
caught at an early stage

4× more Stage I cancers
detected vs. ultrasound

A single blood draw

Our Mission

Finding Cancer Early Is the Key to Beating It

For most cancers, 90% of people survive when the disease is found early. Yet too many of today's tests are inconvenient, costly, and poor at catching cancer in time, so too many people are diagnosed when it is already too late.

Helio Genomics exists to change that. We focus on early detection, when treatment works best, and the chance of beating cancer is highest.

5-Year Survival by Stage at Detection Majority of cancers

Detected early stage 90%

Detected late stage 21%

4× higher Catching cancer early can quadruple the chance of survival. Source: SEER Database.

The Helio Platform

One Platform. A Smarter Way to Detect Cancer.

At the heart of Helio Genomics is an epigenomic, blood-based platform powered by artificial intelligence. It reads the cfDNA methylation patterns that reveal cancer early, and it is built to do more than find one disease. It is designed to change how cancer is detected and monitored across the whole patient journey.

Early Detection

We read proprietary epigenomic signatures, patterns of DNA methylation, that can reveal cancer as early as Stage I from a single blood draw, when treatment works best.

Disease Monitoring

Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and guide decisions over time.

Powered by AI

Machine learning turns complex biomarker data into clear, reliable answers, built on proprietary, patented science developed over nearly a decade.

Explore the Technology

HelioLiver LDT Collection Kit box held in two hands

Available now · Quest Diagnostics

Our First Commercial Test

HelioLiver™ LDT — Our Platform, Proven in the Clinic

HelioLiver LDT is the first test built on the Helio platform, and it is available for clinical use today. It is a simple blood test for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. In the CLiMB trial, HelioLiver detected Stage I liver cancer four times more often than ultrasound, the current standard of care.

44% vs 11%

Stage I HCC detection, HelioLiver vs ultrasound

29% vs 0%

sensitivity for lesions under 2cm

10–14 days

average turnaround time

Validated in the CLiMB trial and published in the Journal of Hepatology, May 2026. Now available to order through Quest Diagnostics.

Discover HelioLiver For Providers

The Science & Proof

Backed by Nearly a Decade of Peer-Reviewed Science

Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection — with foundational research published in some of the world's most respected scientific journals.

2016

Founded with a proprietary, patented methylation profile of novel cancer biomarkers

2017

Early methylation detection research published in Nature Materials and PNAS

2021

An AI and machine learning detection method was published in Nature Communications

2026

CLiMB trial results published in the Journal of Hepatology

Read Our Research

Why It Matters

Why Early Detection Changes Everything

When cancer is caught early, while it is still localised, survival rates are far higher, and many more treatment options are open. Closing the gap between late and early diagnosis, beginning with the liver, is the heart of what we do.

Learn About Early Detection

37% 3%

37%

Early-stage
(localised)

Advanced-stage
(distant)

Five-year survival falls sharply from early-stage to advanced-stage liver cancer · SEER Database

Partners & Recognition

We Collaborate with Leaders in Clinical Care

Bringing groundbreaking cancer detection to patients takes partnership. Helio Genomics works alongside leading healthcare and technology organisations to expand access to early testing, including clinical availability through Quest Diagnostics, one of the largest diagnostic networks in the United States, and a strategic commercial partnership with Syneos Health.